Clinical trials: Stage 1 Acute Kidney Injury
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Myeloma and Plasma Cell Neoplasm, Renal Failure
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
RATIONALE: Dexamethasone is used to treat multiple myeloma. Drugs used in chemotherapy may stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416897
- Testing
- chemotherapy, dexamethasone, plasmapheresis
- Where
- 39 sites in United Kingdom
- Volunteers
- 280 people
- Sponsor
- University of Glasgow
Kidney Failure
Far Infrared Treatment for Kidney Diseases
Renal failure or kidney failure is a situation in which the kidneys fail to function adequately. It is divided into acute and chronic forms; either form may be due to a large number of other medical problems.
- Trial name
- NCT00599391
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- GAAD Medical Research Institute Inc.
Covid19, Stage 1 Acute Kidney Injury
Phase 2a MIB-626 vs. Placebo COVID-19
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by…
- Trial name
- NCT05038488
- Testing
- MIB-626, Home Treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Metro International Biotech, LLC